| 李 阁,谷瑞雪,刘 旭.Her-2阳性乳腺癌靶向治疗药物的研究进展[J].肿瘤学杂志,2020,26(1):1-6. |
| Her-2阳性乳腺癌靶向治疗药物的研究进展 |
| Research Progress in Treatment of Her-2-Positive Breast Cancer with Targeted Agents |
| 投稿时间：2019-04-29 |
| DOI：10.11735/j.issn.1671-170X.2020.01.B001 |
|
 |
| 中文关键词: Her-2 乳腺肿瘤 靶向治疗 |
| 英文关键词:Her-2 breast neoplasms targeted therapy |
| 基金项目:国家自然科学基金面上项目（81372837） |
|
| 摘要点击次数: 2735 |
| 全文下载次数: 483 |
| 中文摘要: |
| 摘 要：Her-2阳性乳腺癌患者预后较差。近年来化疗序贯曲妥珠单抗1年的辅助治疗已成为早期Her-2阳性乳腺癌患者的标准治疗方案，曲妥珠单抗的应用使乳腺癌患者的复发风险降低了40%，然而长期随访数据表明，15%~24%患者仍面临复发风险。后续抗Her-2药物的研制主要集中在预防和克服耐药性方面，帕妥珠单抗、拉帕替尼、T-DM1、来那替尼和吡咯替尼等药物研发改善了Her-2阳性乳腺癌患者的辅助治疗空间。 |
| 英文摘要: |
| Abstract：Breast cancer with Her-2+ phenotype indicates an unfavorable prognosis for patients. Over the past years，the adjuvant therapy with chemotherapy plus 1-year administration of trastuzumab has become a standard treatment for early-stage Her-2+ breast cancer patients，which reduced the risk of relapse by 40%. However，long-term follow-up data show that 15% to 24% of patients still face the risk of recurrence. The newly emerging anti-Her-2 agents such as pertuzumab，lapatinib，T-DM1，neratinib and pyrotinib，mainly focusing on the prevention and overcome of drug resistance，have improved the efficacy of adjuvant therapy for Her-2+ breast cancer patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |